Literature DB >> 14675039

Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis.

Samih H Nasr1, Glen S Markowitz, M Barry Stokes, Surya V Seshan, Elsa Valderrama, Gerald B Appel, Pierre Aucouturier, Vivette D D'Agati.   

Abstract

BACKGROUND: Renal disease related to the deposition of monoclonal immunoglobulins containing both heavy and light chains can occur in type 1 cryoglobulinemia, Randall type light and heavy chain deposition disease (LHCDD), and immunotactoid glomerulonephritis. We report a novel phenotype of glomerular injury that does not conform to any of the previously described patterns of glomerular involvement by monoclonal gammopathy.
METHODS: Ten cases of unclassifiable proliferative glomerulonephritis manifesting glomerular monoclonal immunoglobulin G (IgG) deposits were identified retrospectively from the archives of the Renal Pathology Laboratory of Columbia University over the past 3 years (biopsy incidence 0.21%).
RESULTS: The monoclonal immunoglobulins formed granular electron dense deposits in mesangial, subendothelial, and subepithelial sites, mimicking ordinary immune complex-mediated glomerulonephritis and producing a diffuse endocapillary proliferative or membranoproliferative glomerulonephritis. However, by immunofluorescence, the deposits were monoclonal, staining for a single light chain isotype and a single gamma subclass (including two IgG1kappa, one IgG1lambda, one IgG2lambda, four IgG3kappa, and one IgG3lambda). All cases stained for the three constant domains of the gamma heavy chain (CH1, CH2, and CH3), suggesting deposition of a nondeleted immunoglobulin molecule. Tissue fixation of complement was observed in 90% of cases, and 40% of patients had hypocomplementemia. Clinical presentations included renal insufficiency in 80% (mean serum creatinine 2.8 mg/dL, range 0.9 to 8.0), proteinuria in 100% (mean urine protein 5.8 g/day; range 1.9 to 13.0), nephrotic syndrome in 44%, and microhematuria in 60%. A monoclonal serum protein with the same heavy and light chain isotype as that of the glomerular deposits was identified in 50% of cases (including three IgGkappa and two IgGlambda); however, no patient had clinical or laboratory features of type 1 cryoglobulinemia. No patient had overt myeloma or lymphoma at presentation or over the course of follow-up (mean 12 months).
CONCLUSION: Glomerular deposition of monoclonal IgG can produce a proliferative glomerulonephritis that mimics immune-complex glomerulonephritis by light and electron microscopy. Proper recognition of this entity requires confirmation of monoclonality by staining for the gamma heavy chain subclasses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14675039     DOI: 10.1111/j.1523-1755.2004.00365.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  68 in total

1.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

2.  Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft.

Authors:  Samih H Nasr; Sanjeev Sethi; Lynn D Cornell; Mary E Fidler; Mark Boelkins; Fernando C Fervenza; Fernando G Cosio; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

3.  Chronological change of renal pathological findings in the proliferative glomerulonephritis with monoclonal IgG deposits considered to have recurred early after kidney transplantation.

Authors:  Takayuki Katsuno; Masashi Kato; Takashi Fujita; Naotake Tsuboi; Ryohei Hattori; Yasuhiko Ito; Shoichi Maruyama
Journal:  CEN Case Rep       Date:  2019-02-25

4.  New-onset haematoproteinuria in a 63-year-old man with intraperitoneal lymph node enlargement.

Authors:  Akihiro Minakawa; Shuichi Hisanaga; Yuji Sato; Shouichi Fujimoto
Journal:  BMJ Case Rep       Date:  2016-02-23

5.  Non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis: rare case of long term remission with chemotherapy: a case report.

Authors:  Hala Alshayeb; Barry M Wall
Journal:  Cases J       Date:  2009-09-15

6.  Proliferative glomerulonephritis with monoclonal IgM-κ deposits in chronic lymphocytic leukemia/small lymphocytic leukemia: case report and review of the literature.

Authors:  Yuji Oe; Kensuke Joh; Mitsuhiro Sato; Yoshio Taguma; Yasushi Onishi; Keisuke Nakayama; Toshinobu Sato
Journal:  CEN Case Rep       Date:  2013-03-01

7.  A Case of Monoclonal Gammopathy of Renal Significance.

Authors:  Jonathan J Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-18       Impact factor: 8.237

8.  Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin G deposits leads to rapid graft loss after kidney transplantation: a case report.

Authors:  Kunio Kawanishi; Kazuho Honda; Shigeru Horita; Junki Koike; Tomokazu Shimizu; Kazunari Tanabe; Yutaka Yamaguchi; Kosaku Nitta
Journal:  CEN Case Rep       Date:  2013-12-08

Review 9.  Dysproteinemias and Glomerular Disease.

Authors:  Nelson Leung; Maria E Drosou; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

10.  Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490.

Authors:  Petya Dimitrova; Valeriya Gyurkovska; Irina Shalova; Luciano Saso; Nina Ivanovska
Journal:  J Inflamm (Lond)       Date:  2009-05-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.